Page 124 - 磁共振成像2024年7期电子刊

磁共振成像 2024年7月第15卷第7期 Chin J Magn Reson Imaging, Jul, 2024, Vol. 15, No. 7 临床研究｜｜Clinical Articles

2020: GLOBOCAN estimates of incidence and mortality worldwide j.crad.2019.12.021.
for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): [19] CHEN Y, PANDA A, PAHWA S, et al. Three-dimensional MR
209-249. DOI: 10.3322/caac.21660. fingerprinting for quantitative breast imaging[J]. Radiology, 2019,
[2] WAKS A G, WINER E P. Breast cancer treatment: a review[J]. JAMA, 290(1): 33-40. DOI: 10.1148/radiol.2018180836.
2019, 321(3): 288-300. DOI: 10.1001/jama.2018.19323. [20] LINDERHOLM B K, HELLBORG H, JOHANSSON U, et al.
[3] 中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学 Significantly higher levels of vascular endothelial growth factor
组 . 中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 中国癌症杂 (VEGF) and shorter survival times for patients with primary operable
志, 2023, 33(12): 1092-1187. DOI: 10.19401/j.cnki.1007-3639.2023.12.004. triple-negative breast cancer[J]. Ann Oncol, 2009, 20(10): 1639-1646.
Breast Cancer Professional Committee of Chinese Anti-Cancer DOI: 10.1093/annonc/mdp062.
Association, Breast Oncology Group of Chinese Medical Association [21] DERAKHSHAN F, REIS-FILHO J S. Pathogenesis of triple-negative
Oncology Branch. Guidelines for breast cancer diagnosis and treatment breast cancer[J/OL]. Annu Rev Pathol, 2022, 17: 181-204 [2024-02-26].
by China Anti-cancer Association(2024 edition)[J]. China Oncol, 2023, https://pubmed.ncbi.nlm.nih.gov/35073169/. DOI: 10.1146/annurev-pathol-
33(12): 1092-1187. DOI: 10.19401/j.cnki.1007-3639.2023.12.004. 042420-093238.
[4] 李方正, 李芹, 郑召龙, 等 . 合成 MRI临床应用的研究进展[J]. 放射学 [22] DING J H, XIAO Y, ZHAO S, et al. Integrated analysis reveals the
实践, 2022, 37(3): 402-406. DOI: 10.13609/j.cnki.1000-0313.2022.03.022. molecular features of fibrosis in triple-negative breast cancer[J/OL].
LI F Z, LI Q, ZHENG Z L, et al. Research progress of clinical Mol Ther Oncolytics, 2022, 24: 624-635 [2024-02-26]. https://pubmed.
application of synthetic MRI[J]. Radiol Pract, 2022, 37(3): 402-406. ncbi.nlm.nih.gov/35284626/. DOI: 10.1016/j.omto.2022.02.003.
DOI: 10.13609/j.cnki.1000-0313.2022.03.022. [23] WANG S, LI J H, ZHU D R, et al. Contrast-enhanced magnetic
[5] JI S, YANG D J, LEE J, et al. Synthetic MRI: technologies and resonance (MR) T1 mapping with low-dose gadolinium-diethylenetriamine
applications in neuroradiology[J]. J Magn Reson Imaging, 2022, 55(4): pentaacetic acid (Gd-DTPA) is promising in identifying clear cell renal
1013-1025. DOI: 10.1002/jmri.27440. cell carcinoma histopathological grade and differentiating fat-poor
[6] HWANG K P, FUJITA S. Synthetic MR: physical principles, clinical angiomyolipoma[J]. Quant Imaging Med Surg, 2020, 10(5): 988-998.
implementation, and new developments[J]. Med Phys, 2022, 49(7): DOI: 10.21037/qims-19-723.
4861-4874. DOI: 10.1002/mp.15686. [24] 中国临床肿瘤学会乳腺癌专家委员会, 中国抗癌协会乳腺癌专业委
[7] LIU J R, XU M Y, REN J L, et al. Synthetic MRI, multiplexed sensitivity 员会, 中华医学会外科学分会乳腺外科学组 . 中国年轻乳腺癌诊疗
encoding, and BI-RADS for benign and malignant breast cancer 专 家 共 识 (2022)[J]. 中 华 医 学 杂 志 , 2023, 103(6): 387-403. DOI:
discrimination[J/OL]. Front Oncol, 2022, 12: 1080580 [2024-02-26]. https:// 10.3760/cma.j.cn112137-20220907-01895.
pubmed.ncbi.nlm.nih.gov/36818669/. DOI: 10.3389/fonc.2022.1080580. Breast Cancer expert Committee of Chinese Clinical Oncology Society,
[8] LI X J, FAN Z C, JIANG H N, et al. Synthetic MRI in breast cancer: Breast Cancer Professional Committee of China Anti-Cancer Association,
differentiating benign from malignant lesions and predicting Breast surgery Group of Chinese Medical Association surgery
immunohistochemical expression status[J/OL]. Sci Rep, 2023, 13(1): Association. Expert consensus on the diagnosis and treatment of young
17978 [2024-02-26]. https://pubmed. ncbi. nlm. nih. gov/37864025/. DOI: breast cancer in China (2022 Edition)[J]. Natl Med J China, 2023, 103(6):
10.1038/s41598-023-45079-2. 387-403. DOI: 10.3760/cma.j.cn112137-20220907-01895.
[9] HE H, SONG M N, TIAN Z R, et al. Multiparametric MRI model with [25] 占丹, 黄艳芳, 李平, 等 . 多模态 MRI 技术在三阴性与非三阴性乳腺
synthetic MRI, DWI multi-quantitative parameters, and differential 癌中的诊断价值对比[J]. 实用放射学杂志, 2021, 37(9): 1455-1458.
sub-sampling with Cartesian ordering enables BI-RADS 4 lesions DOI: 10.3969/j.issn.1002-1671.2021.09.013.
diagnosis with high accuracy[J/OL]. Front Oncol, 2023, 13: 1180131 ZHAN D, HUANG Y F, LI P, et al. A comparative study on diagnostic
[2024-02-26]. https://pubmed.ncbi.nlm.nih.gov/38250550/. DOI: 10.3389/ value of multimodal MRI between triple negative breast cancer and
fonc.2023.1180131. non-triple negative breast cancer[J]. J Pract Radiol, 2021, 37(9):
[10] 余雪燕, 周智鹏, 童秋云, 等 . 合成 MRI 鉴别乳腺良恶性及预测乳腺 1455-1458. DOI: 10.3969/j.issn.1002-1671.2021.09.013.
癌 淋 巴 结 转 移 的 应 用 价 值 [J]. 临 床 放 射 学 杂 志 , 2023, 42(2): [26] MUMIN N A, RAMLI HAMID M T, WONG J H D, et al. Magnetic
244-251. DOI: 10.13437/j.cnki.jcr.2023.02.014. resonance imaging phenotypes of breast cancer molecular subtypes: a
YU X Y, ZHOU Z P, TONG Q Y, et al. Application value of synthetic systematic review[J/OL]. Acad Radiol, 2022, 29(Suppl 1): S89-S106
MRI in the differential diagnosis of denign and malignant breast [2024-02-26]. https://pubmed.ncbi.nlm.nih.gov/34481705/. DOI: 10.1016/
lesions and prognosis lymph node metastasis of breast cancer[J]. J Clin j.acra.2021.07.017.
Radiol, 2023, 42(2): 244-251. DOI: 10.13437/j.cnki.jcr.2023.02.014. [27] SZEP M, PINTICAN R, BIANCA B C, et al. Multiparametric MRI
[11] DU S Y, GAO S, ZHANG L N, et al. Improved discrimination of features of breast cancer molecular subtypes[J]. Medicina, 2022,
molecular subtypes in invasive breast cancer: comparison of multiple 58(12): 1716. DOI: 10.3390/medicina58121716.
quantitative parameters from breast MRI[J/OL]. Magn Reson Imaging, [28] 郑璇, 李艳翠, 彭如臣 . 多参数 MRI在原发性乳腺癌不同分子亚型中
2021, 77: 148-158 [2024-02-26]. https://pubmed. ncbi. nlm. nih. gov/ 的 诊 断 价 值 研 究 [J]. 磁 共 振 成 像 , 2023, 14(5): 104-109. DOI:
33309922/. DOI: 10.1016/j.mri.2020.12.001. 10.12015/issn.1674-8034.2023.05.019.
[12] ZHANG Q, ZHAO Y, NIE J, et al. Pretreatment synthetic MRI features ZHENG X, LI Y C, PENG R C. The value of muti-parametric MRI in
for triple-negative breast cancer[J/OL]. Clin Radiol, 2024, 79(2): different molecular subtypes of primary breast cancer[J]. Chin J Magn Reson
e219-e226 [2024-02-26]. https://pubmed.ncbi.nlm.nih.gov/37935611/. Imag, 2023, 14(5): 104-109. DOI: 10.12015/issn.1674-8034.2023.05.019.
DOI: 10.1016/j.crad.2023.10.015. [29] YUEN S, MONZAWA S, YANAI S, et al. The association between
[13] KAZAMA T, TAKAHARA T, KWEE T C, et al. Quantitative values MRI findings and breast cancer subtypes: focused on the combination
from synthetic MRI correlate with breast cancer subtypes[J/OL]. Life, patterns on diffusion-weighted and T2-weighted images[J]. Breast
2022, 12(9): 1307 [2024-02-26]. https://pubmed.ncbi.nlm.nih.gov/36143344/. Cancer, 2020, 27(5): 1029-1037. DOI: 10.1007/s12282-020-01105-z.
DOI: 10.3390/life12091307. [30] KIM J J, KIM J Y, SUH H B, et al. Characterization of breast cancer
[14] 赵睿萌, 杜思瑶, 郭梁存, 等 . 合成 MRI 鉴别诊断乳腺癌不同分子分 subtypes based on quantitative assessment of intratumoral
型及三阴性与非三阴性乳腺癌的价值[J]. 中华放射学杂志, 2022, heterogeneity using dynamic contrast-enhanced and diffusion-weighted
56(6): 636-642. DOI: 10.3760/cma.j.cn112149-20210721-00503. magnetic resonance imaging[J]. Eur Radiol, 2022, 32(2): 822-833.
ZHAO R M, DU S Y, GUO L C, et al. The value of synthetic MRI in DOI: 10.1007/s00330-021-08166-4.
identifying different molecular types of breast cancer and triple [31] UEMATSU T, KASAMI M, YUEN S. Triple-negative breast cancer:
negative and non triple negative breast cancer[J]. Chin J Radiol, 2022, correlation between MR imaging and pathologic findings[J].
56(6): 636-642. DOI: 10.3760/cma.j.cn112149-20210721-00503. Radiology, 2009, 250(3): 638-647. DOI: 10.1148/radiol.2503081054.
[15] GAO W B, YANG Q X, LI X H, et al. Synthetic MRI with quantitative [32] MATSUBAYASHI R, MATSUO Y, EDAKUNI G, et al. Breast masses
mappings for identifying receptor status, proliferation rate, and with peripheral rim enhancement on dynamic contrast-enhanced MR
molecular subtypes of breast cancer[J/OL]. Eur J Radiol, 2022, 148: images: correlation of MR findings with histologic features and
110168 [2024-02-26]. https://pubmed.ncbi.nlm.nih.gov/35078137/. DOI: expression of growth factors[J]. Radiology, 2000, 217(3): 841-848.
10.1016/j.ejrad.2022.110168. DOI: 10.1148/radiology.217.3.r00dc07841.
[16] MATSUDA M, TSUDA T, EBIHARA R, et al. Triple-negative breast [33] YUAN C R, JIN F, GUO X L, et al. Correlation analysis of breast
cancer on contrast-enhanced MRI and synthetic MRI: a comparison cancer DWI combined with DCE-MRI imaging features with
with non-triple-negative breast carcinoma[J/OL]. Eur J Radiol, 2021, molecular subtypes and prognostic factors[J/OL]. J Med Syst, 2019,
142: 109838 [2024-02-26]. https://pubmed. ncbi. nlm. nih. gov/34217136/. 43(4): 83 [2024-02-26]. https://pubmed. ncbi. nlm. nih. gov/30810823/.
DOI: 10.1016/j.ejrad.2021.109838. DOI: 10.1007/s10916-019-1197-5.
[17] BALTZER P, MANN R M, IIMA M, et al. Diffusion-weighted imaging [34] COSTANTINI M, BELLI P, RINALDI P, et al. Diffusion-weighted
of the breast-a consensus and mission statement from the EUSOBI imaging in breast cancer: relationship between apparent diffusion
International Breast Diffusion-Weighted Imaging working group[J]. coefficient and tumour aggressiveness[J]. Clin Radiol, 2010, 65(12):
Eur Radiol, 2020, 30(3): 1436-1450. DOI: 10.1007/s00330-019-06510-3. 1005-1012. DOI: 10.1016/j.crad.2010.07.008.
[18] MATSUDA M, KIDO T, TSUDA T, et al. Utility of synthetic MRI in [35] YOUK J H, SON E J, CHUNG J, et al. Triple-negative invasive breast
predicting the Ki-67 status of oestrogen receptor-positive breast cancer: cancer on dynamic contrast-enhanced and diffusion-weighted MR
a feasibility study[J/OL]. Clin Radiol, 2020, 75(5): 398.e1-398398.e8 imaging: comparison with other breast cancer subtypes[J]. Eur Radiol,
[2024-02-26]. https://pubmed.ncbi.nlm.nih.gov/32019671/. DOI: 10.1016/ 2012, 22(8): 1724-1734. DOI: 10.1007/s00330-012-2425-2.

https://www.chinesemri.com ·117 ·